---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-244711"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:42:07.307485+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nurix appoints Edward C. Saltzman to board of directors

## Summary
- Appointed effective Sept 12, 2022 as Class II director with term through 2025 annual meeting.
- Received initial option for 50,000 shares vesting over 3 years; annual option of 25,000 shares.
- Will serve on Compensation Committee and Development Advisory Committee.
- Saltzman has over 30 years biopharma strategy experience, currently Head of Biotech Strategy at Lumanity.
- Founder of Defined Health, sold to Cello Health; brings strategic development expertise.

## SEC filing metadata
- accession: 0001193125-22-244711
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/0001193125-22-244711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/d408311d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-244711
- JSON: https://secwatch.observer/filing/0001193125-22-244711.json
- Plain text: https://secwatch.observer/filing/0001193125-22-244711.txt

## Key facts
- Executive change
  Edward C. Saltzman was appointed as director at Nurix Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On September 12, 2022, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Edward C. Saltzman to serve as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”) and the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/0001193125-22-244711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.